Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > EphA2


Brief Information

Name:Ephrin type-A receptor 2
Target Synonym:EC:,Epithelial Cell Receptor Protein Tyrosine Kinase,Ephrin type-A receptor 2,Epithelial cell kinase,EPHA2,EPH Receptor A2,Tyrosine-Protein Kinase Receptor ECK,ECK,Soluble EPHA2 Variant 1,EC,CTRCT6,ARCC2,CTPP1,CTPA,Receptor, EphA2,EC 2.7.10
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
EP2-H82E4 Human Biotinylated Human EphA2 Protein, His,Avitag™ (MALS verified)
ACRO Quality

Part of Bioactivity data

EphA2 MALS images

The purity of Biotinylated Human EphA2 Protein, His,Avitag (Cat. No. EP2-H82E4) is more than 95% and the molecular weight of this protein is around 55-70 kDa verified by SEC-MALS.


Immobilized Biotinylated Human EphA2 Protein, His,Avitag (Cat. No. EP2-H82E4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human Ephrin-A1, Fc Tag (Cat. No. EF1-H5251) with a linear range of 0.1-1 ng/mL (QC tested).

Synonym Name



Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Regorafenib DAST; BAY-73-4506 Approved Bayer AG Stivarga, Resihance United States Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Leukemia, Myeloid, Acute; Sarcoma; Gastrinoma; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Peritoneal Neoplasms; Gastrointestinal Stromal Tumors; Bile Duct Neoplasms; Fallopian Tube Neoplasms; Esophageal adenocarcinoma; Adenoma; Thyroid Neoplasms; Lung Neoplasms; Thymoma; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Somatostatinoma; Carcinoma, Islet Cell; Ovarian Neoplasms; Liver Neoplasms; Hemangiosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Carcinoid Tumor; Insulinoma; Solid tumours; Colonic Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Carcinoma, Transitional Cell; Carcinoma, Adenoid Cystic; Glucagonoma Details
Dasatinib Hydrate BMS-354825; NSC-732517 Approved Bristol-Myers Squibb Company 施达赛, Spricel, Sprycel, Spraysel United States Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma Bristol-Myers Squibb Company 2006-06-28 Astrocytoma; Intraocular Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Lung Neoplasms; Gastrointestinal Stromal Tumors; Giant Cell Tumor of Bone; Primary Myelofibrosis; Gliosarcoma; Burkitt Lymphoma; Peritoneal Neoplasms; Leukemia, Myeloid, Chronic-Phase; Sarcoma, Ewing; Neurofibrosarcoma; Sarcoma; Cholangiocarcinoma; Brain Neoplasms; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Prostatic Neoplasms; Neoplasm Metastasis; Mastocytosis; Melanoma; Tongue Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Large Granular Lymphocytic; Leukemia, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Heart Arrest; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Hemangiopericytoma; Sarcoma, Alveolar Soft Part; Uterine Neoplasms; Laryngeal Neoplasms; Waldenstrom Macroglobuli Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
18F-Dasatinib 18F-SKI-249380; [18F]-Fluoro-BMS-354825; [18F]Dasatinib; [18F]SKI-249380; [18F]Fluoro-BMS-354825 Phase 1 Clinical Memorial Sloan Kettering Cancer Center Bone Marrow Neoplasms; Carcinoma; Neoplasms; Sarcoma; Diagnostic agents; Lymphoma; Melanoma Details
siRNA-EphA2-DOPC Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Solid tumours; Ovarian Neoplasms; Pancreatic Neoplasms Details
BT-5528 BT-5528; BT5528 Phase 2 Clinical Bicycle Therapeutics Ovarian Neoplasms; Head and Neck Neoplasms; Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message